Research programme: serotonin 2C receptor agonists - Vernalis/Roche

Drug Profile

Research programme: serotonin 2C receptor agonists - Vernalis/Roche

Alternative Names: VER 3323; VER 5384; VER 5593

Latest Information Update: 16 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vernalis
  • Class
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 03 Dec 2003 Roche has selected a development candidate from the research programme for obesity for preclinical studies
  • 03 Oct 2003 Vernalis Group has merged with British Biotech to form Vernalis
  • 27 Jun 2003 Vernalis plans to select a new development candidate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top